Welcome to BeiMedPlus

BeiGene's medical website with resources for healthcare professionals and disease information for patients and caregivers.

Please confirm the option below that best describes you so we can direct you to appropriate resources and information.

I am a...

Healthcare Professional

hcp

Patient / Caregiver

patient

BeiGene Employee

employee

I am from...

GLOBAL (ex-US) / EN

/

GLOBAL (ex-US) / EN

pts-en

France / FR

fr

Germany / DE

de

Italy / IT

it

Spain / ES

es

Sweden / SE

se

Switzerland / DE

ch-de

Switzerland / FR

ch-fr

Switzerland / IT

ch-it

United States / EN

us

Skip to content

Login / Register

Select Your Location:

Global

Resource Center
- Events Calendar
- Congress Resources
BeiGeneius
Disease Education
- Hematologic Malignancies
- Solid Tumors
Clinical Studies
Contact Us

BeiGeneius Spotlight Series

Stay up-to-date with recent developments and best-practice in your field with these bite-sized updates from our experts.

Heme Spotlights

20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield

00:02:41

Difficult conversations in hematology: Discussing clinical trial enrolment with a patient

Dame Lesley Fallowfield 7th May 2024

B-cell malignancies

20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield

00:03:01

Difficult conversations in hematology: Presenting treatment options for indolent lymphomas

Dame Lesley Fallowfield 7th May 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_Zinzani

00:02:22

A new era for BTK inhibitors in the management of B-cell lymphomas

Pier Luigi Zinzani 2nd May 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_Eichhorst

00:04:11

An expert perspective on what developments to expect in CLL in 2024

Barbara Eichhorst 23rd Apr 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_Eichhorst

00:04:42

ASH 2023 updates: RT1 study of tislelizumab plus zanubrutinib in Richter transformation

Barbara Eichhorst 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_Tedeschi

00:04:44

ASH 2023 updates: BTK inhibitor monotherapy for treatment-naive CLL

Alessandra Tedeschi 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideosTam

00:02:51

ASH 2023 updates: ALPINE study of zanubrutinib vs. ibrutinib in R/R CLL

Constantine Tam 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideosTam

00:03:05

ASH 2023 updates: Switching BTK inhibitor monotherapy

Constantine Tam 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideosTam

00:04:25

ASH 2023 updates: Acquired mutations on BTK inhibitor-containing therapies

Constantine Tam 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideosTam

00:05:18

ASH 2023 updates: Fixed-duration therapy for CLL with a BTK plus BCL2 inhibitor

Constantine Tam 29th Jan 2024

20240705_BeiMedPlus_BeiGeneius_shortvideos_wendtner

00:06:11

The 2023 update to the Onkopedia CLL guidelines

Clemens Wendtner 23rd Aug 2023

00:02:33

The role of BTK inhibitors and genetic testing in Waldenström’s macroglobulinemia

Christian Buske 20th Jul 2023

00:03:18

Managing toxicity with BTK inhibitors in Waldenström’s macroglobulinemia

Christian Buske 20th Jul 2023

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.  The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene

This website is intended for Healthcare Professionals for scientific information exchange purposes only, not for advertising purposes, and does not constitute commercial promotion of any product or recommendation on diagnosis and treatments.

The website may contain information about products or indications that have not yet been approved in your country; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

The safety and efficacy of investigational products or uses may not have been established. Because of the uncertainty of clinical trials, there is no guarantee that compounds will receive regulatory approval and become commercially available for the uses being investigated.

REPORT AN ADVERSE EVENT

adverse_event@beigene.com
Contact Us by Phone

REPORT A PRODUCT COMPLAINT

productscomplaints@beigene.com
Contact Us by Phone

About Us
Privacy Policy
Terms of Use

Information for patients

memo inOncology

© BeiGene 2024. All rights reserved.

You're now leaving the website www.beimedplus.com

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave www.beimedplus.com website. The link will take you to another BeiGene website, the content of which is subject to the locally applicable laws and regulations.

BeiGene Ltd. makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, I want to go back Yes, I would like to continue

You're now leaving the website www.beimedplus.com

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave www.beimedplus.com website. The link will take you to a website owned and operated by an independent party over which BeiGene Ltd. has no control or influence (“third-party website”).

BeiGene Ltd. makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene Ltd. declines any responsibility for third-party information. BeiGene Ltd. makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the target group of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.

Do you really want to leave the www.beimedplus.com website?

No, I want to go back Yes, I would like to continue